What's the next step for a 67-year-old patient with hypertension, currently on lercanidipine (generic name: lercanidipine, an antihypertensive medication) 20 mg once daily (od), with morning blood pressure readings of 139/79 mmHg and evening readings of 147/81 mmHg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Hypertension in a 67-Year-Old Patient on Lercanidipine

For a 67-year-old patient with hypertension on lercanidipine 20 mg once daily with current BP readings of 139/79 mmHg in the morning and 147/81 mmHg in the evening, the next step should be to add a thiazide/thiazide-like diuretic to the current regimen.

Current Status Assessment

The patient is currently on:

  • Lercanidipine 20 mg once daily (maximum dose of this dihydropyridine calcium channel blocker)
  • Morning BP: 139/79 mmHg (borderline controlled)
  • Evening BP: 147/81 mmHg (above target)

Blood Pressure Target Analysis

According to the 2020 International Society of Hypertension (ISH) guidelines 1:

  • Target BP should be <130/80 mmHg for most patients
  • For elderly patients, targets may be individualized based on frailty
  • The evening BP reading of 147/81 mmHg exceeds the hypertension threshold of ≥140/90 mmHg
  • The morning reading is borderline but still above optimal targets

Treatment Algorithm

The patient's current status indicates:

  1. Maximum dose of lercanidipine (20 mg) has been reached
  2. BP is not adequately controlled, particularly in the evening
  3. Patient is 67 years old, which places them in a higher risk category

Following the ISH 2020 drug therapy steps for non-black patients 1:

  1. ✓ Started with a calcium channel blocker (lercanidipine)
  2. ✓ Increased to full dose (20 mg)
  3. Next step: Add a thiazide/thiazide-like diuretic

Evidence for Current Treatment

Lercanidipine is an effective dihydropyridine calcium channel blocker:

  • It has a long receptor half-life and slow onset of action, which helps avoid reflex tachycardia 2
  • At 20 mg/day, it has shown efficacy comparable to amlodipine 10 mg/day 3
  • It is effective in elderly patients (aged 60-85 years) with mild to moderate hypertension 4

Rationale for Adding a Thiazide Diuretic

  1. The patient has reached the maximum dose of lercanidipine (20 mg)
  2. Evening BP readings remain elevated (147/81 mmHg)
  3. The ISH 2020 guidelines specifically recommend adding a thiazide/thiazide-like diuretic as the next step after maximizing calcium channel blocker dosage 1
  4. Combination therapy with different mechanisms of action provides synergistic effects

Monitoring Recommendations

After adding the thiazide/thiazide-like diuretic:

  • Reassess BP control within 4 weeks
  • Target should be to achieve BP <130/80 mmHg throughout the day
  • Monitor for electrolyte abnormalities, particularly potassium and sodium levels
  • Assess for potential side effects of the combination therapy

Common Pitfalls to Avoid

  1. Inadequate dose titration: The patient is already on maximum dose of lercanidipine, so further dose increases are not an option
  2. Switching medications unnecessarily: Lercanidipine appears well-tolerated as no adverse effects were mentioned, so adding a complementary agent is preferable to switching
  3. Ignoring diurnal BP variations: The evening BP elevation is significant and should not be ignored
  4. Delaying treatment intensification: At age 67, prompt BP control is important to reduce cardiovascular risk

If BP remains uncontrolled after adding a thiazide diuretic, the next step would be to consider adding spironolactone or another agent such as an ACE inhibitor or ARB, according to the ISH 2020 treatment algorithm 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Lercanidipine in hypertension.

Vascular health and risk management, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.